Русский
Metformin - Pathogenetic Drug Of First-line In The Treatment Of Type 2 Diabetes
A.V. Zilov
Metformin - pathogenetic drug of first-line in the treatment of type 2 diabetes
We consider the peculiarities of pathogenesis and clinical manifestation of type 2 diabetes mellitus (type 2 diabetes); it is emphasized that type 2 diabetes is part of the metabolic syndrome and it has a typical high risk of atherosclerotic disease of coronary and cerebral vessels. Due to cardio-and angioprotective actions of metformin, we provide the use of this drug in the first-line pharmacotherapy of type 2 diabetes. It is noted that in the major clinical recommendations metformin is considered as the first step in the pharmacotherapy of type 2 diabetes in patients with overweight and obesity.
We consider the peculiarities of pathogenesis and clinical manifestation of type 2 diabetes mellitus (type 2 diabetes); it is emphasized that type 2 diabetes is part of the metabolic syndrome and it has a typical high risk of atherosclerotic disease of coronary and cerebral vessels. Due to cardio-and angioprotective actions of metformin, we provide the use of this drug in the first-line pharmacotherapy of type 2 diabetes. It is noted that in the major clinical recommendations metformin is considered as the first step in the pharmacotherapy of type 2 diabetes in patients with overweight and obesity.
